Liu Lei, Schultz Stephanie A, Saba Adriana, Yang Hyun-Sik, Li Amy, Selkoe Dennis J, Chhatwal Jasmeer P
Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
Alzheimers Dement. 2024 Dec;20(12):8867-8877. doi: 10.1002/alz.14339. Epub 2024 Nov 19.
Though recognized as a potential cause of autosomal dominant Alzheimer's disease, the pathogenicity of many PSEN2 variants remains uncertain. We compared amyloid beta (Aβ) production across all missense PSEN2 variants in the AlzForum database and, when possible, to corresponding PSEN1 variants.
We expressed 74 PSEN2 variants, 21 of which had known, homologous PSEN1 pathogenic variants with the same amino acid substitution, in HEK293 cells lacking presenilin 1/2. Aβ production was compared to age at symptom onset (AAO) and between PSEN1/2 homologs.
Aβ42/40 and Aβ37/42 ratios correlated with AAO across all PSEN2 variants, strongly driven by the subset of PSEN2 variants with PSEN1 homologs. Aβ production across PSEN1/2 homologs was highly correlated. PSEN2 AAO correlated with AAO in PSEN1 homologs but was an average of 18.3 years later.
The existence of a PSEN1 homolog and patterns of Aβ production are important considerations in assessing the pathogenicity of previously reported and new PSEN2 variants.
There were associations between the patterns of amyloid beta (Aβ) production across presenilin 2 (PSEN2) variants and age at symptom onset (AAO). PSEN2 variants for which there is a known, corresponding variant in presenilin 1 (PSEN1) are more likely to have abnormal Aβ production patterns that strongly correlate with AAO, compared to those that lack a known PSEN1 counterpart ("non-homologous PSEN2 variants"). Most PSEN2 variants lacking PSEN1 counterparts had Aβ42/40 ratios close to those of wild-type PSN2, arguing against their pathogenicity. Homologous PSEN1 and PSEN2 variants had correlated Aβ42/40 and Aβ37/42 ratios, indicating that the corresponding amino acid substitution in each presenilin may have largely similar biochemical effects on γ-secretase processivity.
尽管许多早老素2(PSEN2)变异体被认为是常染色体显性阿尔茨海默病的潜在病因,但其致病性仍不确定。我们比较了阿尔茨海默病论坛数据库中所有错义PSEN2变异体的β淀粉样蛋白(Aβ)生成情况,并在可能的情况下与相应的早老素1(PSEN1)变异体进行了比较。
我们在缺乏早老素1/2的人胚肾293(HEK293)细胞中表达了74种PSEN2变异体,其中21种具有已知的、同源的PSEN1致病性变异体且氨基酸替换相同。将Aβ生成情况与症状出现年龄(AAO)进行比较,并在PSEN1/2同源物之间进行比较。
在所有PSEN2变异体中,Aβ42/40和Aβ37/42比值与AAO相关,这在很大程度上是由具有PSEN1同源物的PSEN2变异体子集驱动的。PSEN1/2同源物之间的Aβ生成高度相关。PSEN2的AAO与PSEN1同源物的AAO相关,但平均晚18.3年。
在评估先前报道的和新的PSEN2变异体的致病性时,PSEN1同源物的存在以及Aβ生成模式是重要的考虑因素。
早老素2(PSEN2)变异体的β淀粉样蛋白(Aβ)生成模式与症状出现年龄(AAO)之间存在关联。与那些缺乏已知PSEN1对应物的变异体(“非同源PSEN2变异体”)相比,在早老素1(PSEN1)中有已知对应变异体的PSEN2变异体更有可能具有与AAO强烈相关的异常Aβ生成模式。大多数缺乏PSEN1对应物的PSEN2变异体的Aβ42/40比值接近野生型PSN2,这表明它们不具有致病性。同源的PSEN1和PSEN2变异体的Aβ42/40和Aβ37/42比值相关,这表明每种早老素中相应的氨基酸替换可能对γ-分泌酶的加工过程具有大致相似的生化影响。